Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

723 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 Survey.
Bonnet F, Burty C, Lewden C, Costagliola D, May T, Bouteloup V, Rosenthal E, Jougla E, Cacoub P, Salmon D, Chêne G, Morlat P; Agence Nationale de Recherches sur le Sida et les Hépatites Virales EN19 Mortalité Study Group; Mortavic Study Group. Bonnet F, et al. Clin Infect Dis. 2009 Mar 1;48(5):633-9. doi: 10.1086/596766. Clin Infect Dis. 2009. PMID: 19202627
Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.
del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Pérez-Hoyos S, Jarrín I, Phillips A, Lodi S, van Sighem A, de Wolf W, Sabin C, Bansi L, Justice A, Goulet J, Miró JM, Ferrer E, Meyer L, Seng R, Toulomi G, Gargalianos P, Costagliola D, Abgrall S, Hernán MA; HIV-CAUSAL Collaboration. del Amo J, et al. Clin Infect Dis. 2012 May;54(9):1364-72. doi: 10.1093/cid/cis203. Epub 2012 Mar 28. Clin Infect Dis. 2012. PMID: 22460971 Free PMC article.
Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo).
Joly V, Fagard C, Grondin C, Descamps D, Yazdanpanah Y, Charpentier C, Colin de Verdiere N, Tabuteau S, Raffi F, Cabie A, Chene G, Yeni P; S 130 Apollo Trial Group. Joly V, et al. Among authors: yazdanpanah y. Antimicrob Agents Chemother. 2013 Feb;57(2):758-65. doi: 10.1128/AAC.01662-12. Epub 2012 Nov 19. Antimicrob Agents Chemother. 2013. PMID: 23165467 Free PMC article. Clinical Trial.
[Pulmonary manifestations in HIV-infected patients: a diagnostic approach].
Ferrand H, Crockett F, Naccache JM, Rioux C, Mayaud C, Yazdanpanah Y, Cadranel J. Ferrand H, et al. Among authors: yazdanpanah y. Rev Mal Respir. 2014 Dec;31(10):903-15. doi: 10.1016/j.rmr.2014.04.106. Epub 2014 Aug 31. Rev Mal Respir. 2014. PMID: 25496788 Review. French.
Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.
HIV-CAUSAL Collaboration; Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA. HIV-CAUSAL Collaboration, et al. Clin Infect Dis. 2015 Apr 15;60(8):1262-8. doi: 10.1093/cid/ciu1167. Epub 2015 Jan 6. Clin Infect Dis. 2015. PMID: 25567330 Free PMC article.
723 results